Trial · NCT03131648
Participant flow96
How many started, completed or left each group, period by period.
1 to 20 of 96
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Initial Treatment Period | STARTED | Initial Treatment Period - Tralokinumab 300 mg Q2W | 603 | |
| Initial Treatment Period | STARTED | Initial Treatment Period - Placebo Q2W | 199 | |
| Initial Treatment Period | STARTED | Maintenance Treatment Period - Tralokinumab 300 mg Q2W | 0 | |
| Initial Treatment Period | STARTED | Maintenance Treatment Period - Tralokinumab 300 mg Q4W | 0 | |
| Initial Treatment Period | STARTED | Maintenance Treatment Period - Placebo Q2W | 0 | |
| Initial Treatment Period | STARTED | Maintenance Treatment Period- Placebo Q2W - Tralokinumab Naive | 0 | |
| Initial Treatment Period | STARTED | Open-label Treatment -Tralokinumab 300 mg Q2W + Optional TCS | 0 | |
| Initial Treatment Period | STARTED | Open-label Treatment - Tralokinumab 300 mg Q2W + Optional TCS | 0 | |
| Initial Treatment Period | COMPLETED | Initial Treatment Period - Tralokinumab 300 mg Q2W | 550 | |
| Initial Treatment Period | COMPLETED | Initial Treatment Period - Placebo Q2W | 179 | |
| Initial Treatment Period | COMPLETED | Maintenance Treatment Period - Tralokinumab 300 mg Q2W | 0 | |
| Initial Treatment Period | COMPLETED | Maintenance Treatment Period - Tralokinumab 300 mg Q4W | 0 | |
| Initial Treatment Period | COMPLETED | Maintenance Treatment Period - Placebo Q2W | 0 | |
| Initial Treatment Period | COMPLETED | Maintenance Treatment Period- Placebo Q2W - Tralokinumab Naive | 0 | |
| Initial Treatment Period | COMPLETED | Open-label Treatment -Tralokinumab 300 mg Q2W + Optional TCS | 0 | |
| Initial Treatment Period | COMPLETED | Open-label Treatment - Tralokinumab 300 mg Q2W + Optional TCS | 0 | |
| Initial Treatment Period | NOT COMPLETED | Initial Treatment Period - Tralokinumab 300 mg Q2W | 53 | |
| Initial Treatment Period | NOT COMPLETED | Initial Treatment Period - Placebo Q2W | 20 | |
| Initial Treatment Period | NOT COMPLETED | Maintenance Treatment Period - Tralokinumab 300 mg Q2W | 0 | |
| Initial Treatment Period | NOT COMPLETED | Maintenance Treatment Period - Tralokinumab 300 mg Q4W | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03131648/flow